Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Clinical Study of F182112 in Patients With Relapsed or Refractory Multiple Myeloma

NCT07579234 is registered in ClinicalTrials.gov with Shandong New Time Pharmaceutical Co., LTD as lead sponsor.

NCT NCT07579234
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07579234 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Clinical Study of F182112 in Patients With Relapsed or Refractory Multiple Myeloma
Lead sponsor
Shandong New Time Pharmaceutical Co., LTD
Phase
Phase 3
Overall status
Recruiting
Start date
January 25, 2026
Completion date
January 25, 2029
Enrollment
261 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory multiple myeloma (rrmm)